Zevra Therapeutics
ZVRA | NASDAQ
$9.25
+$0.17 (+1.87%)
At close: Nov 16, 2026, 4:00 PM ET
$9.25
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
+1.87%
(1D)Rating
74.5
+2.0 ptsFundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #33/1021 (Top 3%)
Key Statistics
Market Data
Market Cap $550.42M
1D Range
8.92 9.79
52W Range
8.10 14.75
Valuation (TTM)
PE 7.71
PB 2.30
EV/EBITDA 5.16
Valuation (NTM)
Forward PE 7.21
Forward PEG 12.34
Price Target $24.00
Cash Flow
FCF Yield 7.0%
SBC Adj. FCF Yield 4.6%
SBC Impact -34.0%
Margins
Gross Margin 95.2%
Operating Margin 31.5%
FCF Margin 25.9%
Growth (CAGR)
Revenue 3Y | 5Y 106.2% |
39.0%
Dil EPS 3Y | 5Y 3170.0% |
137.6%
FCF 3Y | 5Y 291.2% |
30.5%
Returns
ROA 24.9%
ROE 38.2%
ROIC 14.8%
Financial Health
Net Cash
$120.92M
Current Ratio 5.46
Interest Coverage 12.71
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company...
Sector Healthcare
Industry Biotechnology
Employees 61
IPO Date Apr 16, 2015
Website zevra.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 3, 2026
EPS
$0.26
Beat +64.97%
YoY:
+2700.00% REV
$37.76M
Beat +1.82%
YoY:
+44.86%Next Earnings
Mar 8, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
7
Consensus
Buy
Price Target
$22.00
Upside
+137.84%
Buy (7)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ZVRA